Limits...
Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration.

Gaebel R, Furlani D, Sorg H, Polchow B, Frank J, Bieback K, Wang W, Klopsch C, Ong LL, Li W, Ma N, Steinhoff G - PLoS ONE (2011)

Bottom Line: Six weeks post infarction, cardiac catheterization showed significant preservation of left ventricular functions in BM and CD105(+)-CB treated groups compared to CB and nontreated MI group (MI-C).Furthermore, cardiac remodeling can be significantly attenuated by BM-hMSC compared to MI-C.Under hypoxic conditions in vitro, remarkably increased extracellular acidification and apoptosis has been detected from CB-hMSC compared to BM and CD105 purified CB-derived hMSC.

View Article: PubMed Central - PubMed

Affiliation: Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Department of Cardiac Surgery, University of Rostock, Rostock, Germany.

ABSTRACT
The possible different therapeutic efficacy of human mesenchymal stem cells (hMSC) derived from umbilical cord blood (CB), adipose tissue (AT) or bone marrow (BM) for the treatment of myocardial infarction (MI) remains unexplored. This study was to assess the regenerative potential of hMSC from different origins and to evaluate the role of CD105 in cardiac regeneration. Male SCID mice underwent LAD-ligation and received the respective cell type (400.000/per animal) intramyocardially. Six weeks post infarction, cardiac catheterization showed significant preservation of left ventricular functions in BM and CD105(+)-CB treated groups compared to CB and nontreated MI group (MI-C). Cell survival analyzed by quantitative real time PCR for human GAPDH and capillary density measured by immunostaining showed consistent results. Furthermore, cardiac remodeling can be significantly attenuated by BM-hMSC compared to MI-C. Under hypoxic conditions in vitro, remarkably increased extracellular acidification and apoptosis has been detected from CB-hMSC compared to BM and CD105 purified CB-derived hMSC. Our findings suggests that hMSC originating from different sources showed a different healing performance in cardiac regeneration and CD105(+) hMSC exhibited a favorable survival pattern in infarcted hearts, which translates into a more robust preservation of cardiac function.

Show MeSH

Related in: MedlinePlus

Heart functions 6 weeks after MI.A. Recovery of cardiac performance shows improvement for hearts with implanted human BM- and CD105-purified CB-hMSC compared to MI-CB hearts. B. Left ventricular functions at both baseline and stress condition assessed by catheterization.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3037376&req=5

pone-0015652-g002: Heart functions 6 weeks after MI.A. Recovery of cardiac performance shows improvement for hearts with implanted human BM- and CD105-purified CB-hMSC compared to MI-CB hearts. B. Left ventricular functions at both baseline and stress condition assessed by catheterization.

Mentions: Hemodynamic measurement of the cardiac performance (Figure 2A) demonstrates an improvement of functional parameters in case of stem cell treatment both under baseline conditions as well as after stress induction. Figure 2A also shows improved endsystolic values and stroke volume for hearts with implanted human BM- and CD105-purified CB-hMSC (MI-CB105) compared to MI-CB. Functional parameters in MI-BM and MI-CD105 groups present significant improvements on ejection fraction (EF) and stroke work (SW), both under baseline and stress induction in comparison to the MI-CB (Figure 2B). Significant values have also been found on stroke volume (SV), endsystolic volume (ESV), maximum pressure (Pmax) and cardiac output (CO; Figure 2B).


Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration.

Gaebel R, Furlani D, Sorg H, Polchow B, Frank J, Bieback K, Wang W, Klopsch C, Ong LL, Li W, Ma N, Steinhoff G - PLoS ONE (2011)

Heart functions 6 weeks after MI.A. Recovery of cardiac performance shows improvement for hearts with implanted human BM- and CD105-purified CB-hMSC compared to MI-CB hearts. B. Left ventricular functions at both baseline and stress condition assessed by catheterization.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3037376&req=5

pone-0015652-g002: Heart functions 6 weeks after MI.A. Recovery of cardiac performance shows improvement for hearts with implanted human BM- and CD105-purified CB-hMSC compared to MI-CB hearts. B. Left ventricular functions at both baseline and stress condition assessed by catheterization.
Mentions: Hemodynamic measurement of the cardiac performance (Figure 2A) demonstrates an improvement of functional parameters in case of stem cell treatment both under baseline conditions as well as after stress induction. Figure 2A also shows improved endsystolic values and stroke volume for hearts with implanted human BM- and CD105-purified CB-hMSC (MI-CB105) compared to MI-CB. Functional parameters in MI-BM and MI-CD105 groups present significant improvements on ejection fraction (EF) and stroke work (SW), both under baseline and stress induction in comparison to the MI-CB (Figure 2B). Significant values have also been found on stroke volume (SV), endsystolic volume (ESV), maximum pressure (Pmax) and cardiac output (CO; Figure 2B).

Bottom Line: Six weeks post infarction, cardiac catheterization showed significant preservation of left ventricular functions in BM and CD105(+)-CB treated groups compared to CB and nontreated MI group (MI-C).Furthermore, cardiac remodeling can be significantly attenuated by BM-hMSC compared to MI-C.Under hypoxic conditions in vitro, remarkably increased extracellular acidification and apoptosis has been detected from CB-hMSC compared to BM and CD105 purified CB-derived hMSC.

View Article: PubMed Central - PubMed

Affiliation: Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Department of Cardiac Surgery, University of Rostock, Rostock, Germany.

ABSTRACT
The possible different therapeutic efficacy of human mesenchymal stem cells (hMSC) derived from umbilical cord blood (CB), adipose tissue (AT) or bone marrow (BM) for the treatment of myocardial infarction (MI) remains unexplored. This study was to assess the regenerative potential of hMSC from different origins and to evaluate the role of CD105 in cardiac regeneration. Male SCID mice underwent LAD-ligation and received the respective cell type (400.000/per animal) intramyocardially. Six weeks post infarction, cardiac catheterization showed significant preservation of left ventricular functions in BM and CD105(+)-CB treated groups compared to CB and nontreated MI group (MI-C). Cell survival analyzed by quantitative real time PCR for human GAPDH and capillary density measured by immunostaining showed consistent results. Furthermore, cardiac remodeling can be significantly attenuated by BM-hMSC compared to MI-C. Under hypoxic conditions in vitro, remarkably increased extracellular acidification and apoptosis has been detected from CB-hMSC compared to BM and CD105 purified CB-derived hMSC. Our findings suggests that hMSC originating from different sources showed a different healing performance in cardiac regeneration and CD105(+) hMSC exhibited a favorable survival pattern in infarcted hearts, which translates into a more robust preservation of cardiac function.

Show MeSH
Related in: MedlinePlus